Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

Imnovid

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
  • O. Fuchs
  • Cardiovascular & hematological disorders drug…
  • 2019
  • Corpus ID: 46897258
Thalidomide and its derivatives (lenalidomide, pomalidomide, avadomide, iberdomide hydrochoride, CC-885 and CC-90009) form the… 
Review
2017
Review
2017
Pomalidomide (Imnovid®; Pomalyst®), an analogue of thalidomide, is an immunomodulatory agent, with several mechanisms of action… 
  • table 1
Review
2017
Review
2017
The National Institute for Health and Care Excellence (NICE), as part of the institute’s single technology appraisal (STA… 
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Review
2014
Review
2014
Abstract Multiple myeloma (MM) is a haematological disease characterized by plasma cells proliferation in bone marrow associated… 
Review
2014
Review
2014
Oral pomalidomide (Imnovid® [EU]; Pomalyst® [USA]) in combination with dexamethasone (in the EU), is approved in several… 
  • figure 1
  • table 1
  • table 2
  • figure 2
2013
2013
Imnovid® ist ein neuer Wirkstoff aus der Klasse der IMiDs® (Immunmodulatoren). Mit einer Standarddosierung von 4 mg (orale Gabe…